Skip header and navigation

Refine By

5 records – page 1 of 1.

Anticholinergic drug use and its association with self-reported symptoms among older persons with and without diabetes.

https://arctichealth.org/en/permalink/ahliterature298928
Source
J Clin Pharm Ther. 2019 Apr; 44(2):229-235
Publication Type
Journal Article
Date
Apr-2019
Author
Niina-Mari Inkeri
Merja Karjalainen
Maija Haanpää
Hannu Kautiainen
Juha Saltevo
Pekka Mäntyselkä
Miia Tiihonen
Author Affiliation
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Source
J Clin Pharm Ther. 2019 Apr; 44(2):229-235
Date
Apr-2019
Language
English
Publication Type
Journal Article
Keywords
Aged
Aged, 80 and over
Cholinergic Antagonists - adverse effects - therapeutic use
Cohort Studies
Cross-Sectional Studies
Diabetes Mellitus - epidemiology
Female
Finland
Humans
Independent living
Male
Practice Patterns, Physicians' - statistics & numerical data
Primary Health Care
Self Report
Surveys and Questionnaires
Abstract
Anticholinergic drug use has been associated with a risk of central and peripheral adverse effects. There is a lack of information on anticholinergic drug use in persons with diabetes. The aim of this study is to investigate anticholinergic drug use and the association between anticholinergic drug use and self-reported symptoms in older community-dwelling persons with and without diabetes.
The basic population was comprised of Finnish community-dwelling primary care patients aged 65 and older. Persons with diabetes were identified according to the ICD-10 diagnostic codes from electronic patient records. Two controls adjusted by age and gender were selected for each person with diabetes. This cross-sectional study was based on electronic primary care patient records and a structured health questionnaire. The health questionnaire was returned by 430 (81.6%) persons with diabetes and 654 (73.5%) persons without diabetes. Data on prescribed drugs were obtained from the electronic patient records. Anticholinergic drug use was measured according to the Anticholinergic Risk Scale. The presence and strength of anticholinergic symptoms were asked in the health questionnaire.
The prevalence of anticholinergic drug use was 8.9% in the total study cohort. There were no significant differences in anticholinergic drug use between persons with and without diabetes. There was no consistent association between anticholinergic drug use and self-reported symptoms.
There is no difference in anticholinergic drug use in older community-dwelling persons with and without diabetes. Anticholinergic drug use should be considered individually and monitored carefully.
PubMed ID
30315583 View in PubMed
Less detail

Glycemic control and health-related quality of life among older home-dwelling primary care patients with diabetes.

https://arctichealth.org/en/permalink/ahliterature293508
Source
Prim Care Diabetes. 2017 Dec; 11(6):577-582
Publication Type
Journal Article
Date
Dec-2017
Author
Anna-Kaisa Aro
Merja Karjalainen
Miia Tiihonen
Hannu Kautiainen
Juha Saltevo
Maija Haanpää
Pekka Mäntyselkä
Author Affiliation
Institute of Public Health and Clinical Nutrition, General Practice, University of Eastern Finland, Finland; Rantakylä Health Center, Siunsote, Finland. Electronic address: koistine@student.uef.fi.
Source
Prim Care Diabetes. 2017 Dec; 11(6):577-582
Date
Dec-2017
Language
English
Publication Type
Journal Article
Keywords
Activities of Daily Living
Age Factors
Aged
Aged, 80 and over
Aging
Biomarkers - blood
Blood Glucose - metabolism
Cognition
Cross-Sectional Studies
Diabetes Mellitus - blood - diagnosis - psychology - therapy
Female
Finland
Geriatric Assessment
Glycated Hemoglobin A - metabolism
Humans
Independent living
Male
Mental health
Mental Status and Dementia Tests
Mobility Limitation
Predictive value of tests
Primary Health Care
Quality of Life
Risk factors
Self Care - methods
Time Factors
Treatment Outcome
Abstract
To evaluate the health-related quality of life (HRQoL) and functional capacity in relation to glycemic control among older home-dwelling primary care patients.
Electronic patient records were used to identify 527 people over 65 years with diabetes. Of these, 259 randomly selected subjects were invited to a health examination and 172 of them attended and provided complete data. The participants were divided into three groups based on the HbA1c: good (HbA1c57mmol/mol (N=29)) glycemic control. HRQoL was measured with the EuroQol EQ-5D questionnaire. Functional and cognitive capacity and mental well-being were assessed with the Lawton Instrumental Activities of Daily Living (IADL) scale, Mini-Mental State Examination (MMSE) and Geriatric Depression Scale (GDS-15).
EQ-5D scores for good, intermediate and poor glycemic control were 0.78; 0.74 and 0.70, p=0.037. Sub-items of mobility (p=0.002) and self-care were the most affected (p=0.031). Corresponding trend was found for IADL, p=0.008. A significant correlation was found between MMSE scores and HbA1c.
Older primary care home-dwelling patients with diabetes and poorer glycemic control have lower functional capacity and HRQoL, especially in regard to mobility and self-care.
PubMed ID
28754430 View in PubMed
Less detail

Incidence of Bisphosphonate Use in Relation to Diagnosis of Alzheimer's Disease in Community-Dwelling Persons.

https://arctichealth.org/en/permalink/ahliterature294596
Source
J Am Geriatr Soc. 2016 09; 64(9):e48-9
Publication Type
Letter
Date
09-2016

Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature291615
Source
Eur J Clin Pharmacol. 2017 Sep; 73(9):1149-1158
Publication Type
Journal Article
Date
Sep-2017
Author
Heidi Juntunen
Heidi Taipale
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Miia Tiihonen
Author Affiliation
Kuopio Research Centre of Geriatric Care, University of Eastern Finland, P.O.B 1627, -70211, Kuopio, FI, Finland.
Source
Eur J Clin Pharmacol. 2017 Sep; 73(9):1149-1158
Date
Sep-2017
Language
English
Publication Type
Journal Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Diphosphonates - therapeutic use
Drug Utilization - statistics & numerical data
Female
Fibrinolytic Agents - therapeutic use
Finland
Humans
Independent Living - statistics & numerical data
Male
Models, Theoretical
Proton Pump Inhibitors - therapeutic use
Registries
Serotonin Uptake Inhibitors - therapeutic use
Abstract
The aim of this study is to determine the prevalence of use and long-term use (=180 days) of proton pump inhibitors (PPIs) and associated factors among community-dwellers with and without Alzheimer's disease (AD).
MEDALZ cohort encompassed all persons who received a verified diagnosis of AD in Finland during the years 2005-2011 and their age-, sex-, and region of residence-matched comparison persons, including 69,353 persons with and 69,353 persons without AD. Data was derived from several Finnish administrative registers. A mathematical modelling method, PRE2DUP, was used for converting dispensing data to drug use periods (when regular PPI use started and ended). Morbid conditions and concomitant drugs associated with use and long-term use of PPIs were assessed with logistic regression models.
Use of PPIs was more common among comparison persons than persons with AD (39.0 and 35.8%, respectively, p 
Notes
Cites: Am J Med. 2010 Jun;123(6):496-501 PMID 20569750
Cites: Br J Clin Pharmacol. 2004 Jan;57(1):6-14 PMID 14678335
Cites: Drugs Aging. 2014 Apr;31(4):263-82 PMID 24634248
Cites: Int Psychogeriatr. 2016 Jul;28(7):1059-65 PMID 26744954
Cites: Eur J Intern Med. 2017 Jan;37:19-24 PMID 27784575
Cites: Eur J Clin Pharmacol. 2008 Oct;64(10):935-51 PMID 18679668
Cites: Aliment Pharmacol Ther. 2016 Jul;44(1):78-87 PMID 27137875
Cites: J Am Geriatr Soc. 2009 Aug;57(8):1331-46 PMID 19573219
Cites: Arch Med Res. 2012 Nov;43(8):600-8 PMID 23159715
Cites: Clin Epidemiol. 2016 Oct 11;8:363-371 PMID 27785101
Cites: Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):9-16 PMID 27859947
Cites: Res Social Adm Pharm. 2017 Mar - Apr;13(2):358-363 PMID 27033427
Cites: BMC Med. 2016 Nov 9;14 (1):179 PMID 27825371
Cites: Eur Respir J. 2017 Mar 15;49(3):null PMID 28298398
Cites: Eur J Clin Pharmacol. 2007 Nov;63(11):1069-74 PMID 17712552
Cites: JAMA Neurol. 2016 Apr;73(4):410-6 PMID 26882076
Cites: Eur Arch Psychiatry Clin Neurosci. 2015 Aug;265(5):419-28 PMID 25341874
Cites: BMJ Open. 2016 Jul 13;6(7):e012100 PMID 27412109
Cites: J Am Geriatr Soc. 2016 Dec;64(12 ):e291-e296 PMID 27996115
Cites: J Am Geriatr Soc. 2010 May;58(5):880-8 PMID 20406320
Cites: Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1079-87 PMID 27255671
Cites: Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):443-54 PMID 23998981
Cites: Ann Clin Biochem. 2013 Jul;50(Pt 4):315-29 PMID 23592803
Cites: BMC Med Inform Decis Mak. 2015 Mar 25;15:21 PMID 25890003
Cites: Age Ageing. 2013 Mar;42 Suppl 1:i1-57 PMID 23420266
Cites: Eur J Pain. 2017 Apr;21(4):658-667 PMID 27862681
Cites: Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1070-8 PMID 27184012
Cites: Scand J Prim Health Care. 2010 Sep;28(3):154-9 PMID 20586539
Cites: Drugs Aging. 2012 Aug 1;29(8):681-90 PMID 22775478
Cites: Therap Adv Gastroenterol. 2016 Sep;9(5):671-8 PMID 27582879
Cites: Drugs Aging. 2010 Apr 1;27(4):337-49 PMID 20359263
Cites: Neurology. 1984 Jul;34(7):939-44 PMID 6610841
Cites: Drugs Aging. 2010 Jul 1;27(7):545-58 PMID 20583849
PubMed ID
28577224 View in PubMed
Less detail

Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005-2012: A Nationwide Exposure-Matched Cohort Study.

https://arctichealth.org/en/permalink/ahliterature297698
Source
Drugs Aging. 2018 11; 35(11):985-992
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
11-2018
Author
Anna-Maija Tolppanen
Miia Tiihonen
Heidi Taipale
Marjaana Koponen
Antti Tanskanen
Piia Lavikainen
Jari Tiihonen
Sirpa Hartikainen
Author Affiliation
School of Pharmacy, University of Eastern Finland, PL 1627, 70211, Kuopio, Finland. anna-maija.tolppanen@uef.fi.
Source
Drugs Aging. 2018 11; 35(11):985-992
Date
11-2018
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adult
Aged
Aged, 80 and over
Alzheimer Disease - psychology
Cognitive Dysfunction - etiology
Cohort Studies
Estrogens - administration & dosage
Female
Finland - epidemiology
Humans
Independent living
Middle Aged
Prevalence
Abstract
It is unknown whether cognitive status or diagnosed cognitive decline affects estrogen use.
We assessed how common systemic estrogen use was among community-dwellers with Alzheimer's disease (AD) and a matched comparison cohort without AD.
This study included an exposure-matched cohort of all Finnish community-dwelling women who received a clinically verified diagnosis of AD in 2005-2011 (N?=?46,116; index cases) and an equally sized matched comparison cohort without AD. Follow-up began on the matching date (date of the AD diagnosis of the index case). Data on systemic estrogen use were obtained from the prescription register. Use initiation and discontinuation were assessed.
Altogether 3.1% of women with AD and 4.3% of women without AD used estrogen during the follow-up period. Only?
PubMed ID
30317535 View in PubMed
Less detail